Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Papillomavirus Infections × Diphtheria Toxoid × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Human Papillomavirus-Related Cervical Carcinoma 1 Glioma 1 Glioblastoma 1 Advanced Fallopian Tube Carcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 34 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 27 Papillomavirus Vaccines 22 Vaccines 11 Human Papillomavirus Recombinant Vaccine nonavalent 10 Radiotherapy, Intensity-Modulated 7 Human Papillomavirus DNA Tests 7 Colposcopy 7 Cisplatin 7 Carboplatin 6 Vaccines, Synthetic 5 Specimen Handling 5 Educational Status 5 Blood Specimen Collection 5 Vaginal Smears 4 Engerix-B 4 Early Intervention, Educational 4 fludarabine 3 artesunic acid 3 artemisinin 3 Watchful Waiting 3 Surveys and Questionnaires 3 Paclitaxel 3 Methods 3 Imiquimod 3 Hepatitis A Vaccines 3 Cyclophosphamide 3 halofantrine 2 fludarabine phosphate 2 epigallocatechin gallate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03180034 2025-09-04

ESCUDDO

National Cancer Institute (NCI)

Phase 4 Active not recruiting

27,945 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡